Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Lymphoid 2Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 34Bevacizumab 31Carboplatin 28pembrolizumab 24Specimen Handling 19Magnetic Resonance Spectroscopy 17olaparib 15Cisplatin 14liposomal doxorubicin 13Taxes 12Immunoglobulin G 11Gemcitabine 11Disulfides 11Topotecan 9Nivolumab 9Cyclophosphamide 8Biopsy 8Doxorubicin 7mirvetuximab soravtansine 6fludarabine 6niraparib 5Radiation 5Oxaliplatin 5Fulvestrant 5Fluorouracil 5trastuzumab deruxtecan 4cediranib 4Platinum 4Leucovorin 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tazemetostat × Gynecologic × 30 days × Clear all
NCT03348631 2026-05-29

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
62 enrolled 14 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡